This combination specifically targets KRAS‐driven oncogenic signaling in mesenchymal PDAC subtypes, induces tumor cell death, and mediates extensive reprogramming of the immunosuppressive tumor microenvironment—key mechanisms that enhance therapeutic efficacy [7]. Here, KRAS is linked to neoplasm.